vs
亚什兰（ASH）与Axsome Therapeutics, Inc.（AXSM）财务数据对比。点击上方公司名可切换其他公司
亚什兰的季度营收约是Axsome Therapeutics, Inc.的2.0倍（$386.0M vs $191.2M），Axsome Therapeutics, Inc.同比增速更快（57.4% vs -4.7%），过去两年Axsome Therapeutics, Inc.的营收复合增速更高（48.1% vs -18.1%）
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
Jazz Pharmaceuticals是一家全球生物制药企业，专注于肿瘤学与神经科学领域的药物研发及商业化。公司2003年在美国加利福尼亚州成立，目前总部位于爱尔兰都柏林，业务覆盖全球多个核心市场。
ASH vs AXSM — 直观对比
营收规模更大
ASH
是对方的2.0倍
$191.2M
营收增速更快
AXSM
高出62.1%
-4.7%
两年增速更快
AXSM
近两年复合增速
-18.1%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $386.0M | $191.2M |
| 净利润 | $-12.0M | — |
| 毛利率 | 27.2% | — |
| 营业利润率 | -1.6% | -33.1% |
| 净利率 | -3.1% | — |
| 营收同比 | -4.7% | 57.4% |
| 净利润同比 | 92.7% | — |
| 每股收益（稀释后） | $-0.26 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASHAXSM
| Q1 26 | — | $191.2M | ||
| Q4 25 | $386.0M | $196.0M | ||
| Q3 25 | $477.0M | $171.0M | ||
| Q2 25 | $463.0M | $150.0M | ||
| Q1 25 | $479.0M | $121.5M | ||
| Q4 24 | $405.0M | $118.8M | ||
| Q3 24 | $521.0M | $104.8M | ||
| Q2 24 | $544.0M | $87.2M |
净利润ASHAXSM
| Q1 26 | — | — | ||
| Q4 25 | $-12.0M | $-28.6M | ||
| Q3 25 | $31.0M | $-47.2M | ||
| Q2 25 | $-742.0M | $-48.0M | ||
| Q1 25 | $31.0M | $-59.4M | ||
| Q4 24 | $-165.0M | $-74.9M | ||
| Q3 24 | $17.0M | $-64.6M | ||
| Q2 24 | $6.0M | $-79.3M |
毛利率ASHAXSM
| Q1 26 | — | — | ||
| Q4 25 | 27.2% | — | ||
| Q3 25 | 33.3% | — | ||
| Q2 25 | 28.5% | — | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | 27.4% | — | ||
| Q3 24 | 33.2% | — | ||
| Q2 24 | 34.2% | — |
营业利润率ASHAXSM
| Q1 26 | — | -33.1% | ||
| Q4 25 | -1.6% | -13.8% | ||
| Q3 25 | 12.8% | -27.0% | ||
| Q2 25 | -152.9% | -24.5% | ||
| Q1 25 | 10.6% | -46.9% | ||
| Q4 24 | -44.2% | -61.1% | ||
| Q3 24 | 6.1% | -59.8% | ||
| Q2 24 | -11.2% | -89.5% |
净利率ASHAXSM
| Q1 26 | — | — | ||
| Q4 25 | -3.1% | -14.6% | ||
| Q3 25 | 6.5% | -27.6% | ||
| Q2 25 | -160.3% | -32.0% | ||
| Q1 25 | 6.5% | -48.9% | ||
| Q4 24 | -40.7% | -63.1% | ||
| Q3 24 | 3.3% | -61.7% | ||
| Q2 24 | 1.1% | -91.0% |
每股收益（稀释后）ASHAXSM
| Q1 26 | — | — | ||
| Q4 25 | $-0.26 | $-0.55 | ||
| Q3 25 | $0.83 | $-0.94 | ||
| Q2 25 | $-16.21 | $-0.97 | ||
| Q1 25 | $0.65 | $-1.22 | ||
| Q4 24 | $-3.50 | $-1.54 | ||
| Q3 24 | $0.34 | $-1.34 | ||
| Q2 24 | $0.12 | $-1.67 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $304.0M | $305.1M |
| 总债务越低越好 | $1.4B | $70.0M |
| 股东权益账面价值 | $1.9B | — |
| 总资产 | $4.5B | $713.6M |
| 负债/权益比越低杠杆越低 | 0.74× | — |
8季度趋势，按日历期对齐
现金及短期投资ASHAXSM
| Q1 26 | — | $305.1M | ||
| Q4 25 | $304.0M | $322.9M | ||
| Q3 25 | $215.0M | $325.3M | ||
| Q2 25 | $207.0M | $303.0M | ||
| Q1 25 | $168.0M | $300.9M | ||
| Q4 24 | $219.0M | $315.4M | ||
| Q3 24 | $300.0M | $327.3M | ||
| Q2 24 | $399.0M | $315.7M |
总债务ASHAXSM
| Q1 26 | — | $70.0M | ||
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — |
股东权益ASHAXSM
| Q1 26 | — | — | ||
| Q4 25 | $1.9B | $88.3M | ||
| Q3 25 | $1.9B | $73.7M | ||
| Q2 25 | $1.9B | $73.1M | ||
| Q1 25 | $2.6B | $53.2M | ||
| Q4 24 | $2.6B | $57.0M | ||
| Q3 24 | $2.9B | $92.9M | ||
| Q2 24 | $3.0B | $102.9M |
总资产ASHAXSM
| Q1 26 | — | $713.6M | ||
| Q4 25 | $4.5B | $689.8M | ||
| Q3 25 | $4.6B | $669.3M | ||
| Q2 25 | $4.6B | $639.8M | ||
| Q1 25 | $5.2B | $596.7M | ||
| Q4 24 | $5.2B | $568.5M | ||
| Q3 24 | $5.6B | $561.5M | ||
| Q2 24 | $5.7B | $548.2M |
负债/权益比ASHAXSM
| Q1 26 | — | — | ||
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.52× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.45× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.0M | — |
| 自由现金流经营现金流 - 资本支出 | $111.0M | — |
| 自由现金流率自由现金流/营收 | 28.8% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $200.0M | — |
8季度趋势，按日历期对齐
经营现金流ASHAXSM
| Q1 26 | — | — | ||
| Q4 25 | $125.0M | $-18.7M | ||
| Q3 25 | $40.0M | $1.0M | ||
| Q2 25 | $115.0M | $-32.4M | ||
| Q1 25 | $9.0M | $-43.4M | ||
| Q4 24 | $-30.0M | $-26.2M | ||
| Q3 24 | $80.0M | $-18.6M | ||
| Q2 24 | $127.0M | $-30.1M |
自由现金流ASHAXSM
| Q1 26 | — | — | ||
| Q4 25 | $111.0M | $-18.7M | ||
| Q3 25 | $6.0M | $988.0K | ||
| Q2 25 | $95.0M | $-32.4M | ||
| Q1 25 | $-12.0M | $-43.7M | ||
| Q4 24 | $-53.0M | $-26.2M | ||
| Q3 24 | $42.0M | $-18.7M | ||
| Q2 24 | $98.0M | $-30.2M |
自由现金流率ASHAXSM
| Q1 26 | — | — | ||
| Q4 25 | 28.8% | -9.6% | ||
| Q3 25 | 1.3% | 0.6% | ||
| Q2 25 | 20.5% | -21.6% | ||
| Q1 25 | -2.5% | -36.0% | ||
| Q4 24 | -13.1% | -22.1% | ||
| Q3 24 | 8.1% | -17.9% | ||
| Q2 24 | 18.0% | -34.6% |
资本支出强度ASHAXSM
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 0.0% | ||
| Q3 25 | 7.1% | 0.0% | ||
| Q2 25 | 4.3% | 0.0% | ||
| Q1 25 | 4.4% | 0.3% | ||
| Q4 24 | 5.7% | 0.0% | ||
| Q3 24 | 7.3% | 0.1% | ||
| Q2 24 | 5.3% | 0.1% |
现金转化率ASHAXSM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.71× | — | ||
| Q2 24 | 21.17× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
